KRAS is the most frequently mutated oncogene in human malignancies and is therefore often considered as the ‘holy grail’ of targeted cancer therapies. For many years, however, investigators failed to develop effective selective inhibitors of mutant KRAS. More recently, progress has been made with the development of specific inhibitors of KRASG12C. This mini-review will provide an overview of the clinical trial data with these KRASG12C inhibitors and will take a brief look at a number of other selective KRAS inhibitors.
